Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 2447-2454, July 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kannan, R.
Right arrow Articles by Baker, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kannan, R.
Right arrow Articles by Baker, N.

Compartmental Analysis of Linoleate and Palmitate Turnover in a Murine Carcinoma1

Ramaswamy Kannan, Murad Ookhtens and Nome Baker

Tumor-Lipid Laboratory, Research Service, Veterans Administration Wadsworth Medical Center, Los Angeles 90073, and the Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024

We have carried out a balance study in Ehrlich ascites carcinoma in mice to determine whether large amounts of free fatty acids (FFA) could be diverted to an oxidative fate as suggested by earlier workers. At least 90% of the FFA that turn over in the Ehrlich ascites tumor fluid are incorporated into the cell lipid esters of this carcinoma.

Simultaneous with our balance study, we have compared the metabolic fate of essential and nonessential fatty acids (FA) in vivo in mouse Ehrlich ascites tumors using [1-14C]linoleic acid and [9,10-3H]palmitic acid complexed to mouse serum albumin. We followed the early disappearance of labeled FFA from the tumor system and the appearance of radioactivity in various tumor lipids and calculated rates of esterification and recycling of FA esters to FFA by cancer cells in vivo using multicompartmental analysis. We also estimated rates of "irreversible" disposal of FFA (combined rates of oxidation and transfer to host) in this tumor system. All rates for essential FA were found to be very similar to those for nonessential FA; however, some subtle differences seemed to exist; e.g., linoleate tended to disappear from the extracellular FFA pool faster than did palmitate and to appear in cellular phospholipids more rapidly than did palmitate, but the differences were not statistically significant. The major metabolic pathway for both classes of FFA was participation in an extremely rapid "futile cycle" of FA esterification (primarily into phospholipids) and hydrolysis. This cycle operates approximately 40 to 60 times faster than the rate of net FA esterification required for tumor growth (400 to 600 versus 10 nmol FA per min per 7-ml tumor). The "irreversible" disposal of FFA, based upon tracer studies with both essential and nonessential FFA, was approximately 6 times faster than the rate of FFA utilization for net growth.

1 This investigation was supported in part by the Veterans Administration Medical Research and NIH-USPHS Grants CA 15813 and CA 05651. Preliminary data from this study were presented at the Federation of American Societies for Experimental Biology Meeting, Atlantic City, N. J., April 1978 (14).

Received 12/10/79. Accepted 4/11/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.